News | Intensity Modulated Radiation Therapy (IMRT) | October 25, 2017

UZ Leuven Treats First European Patient on Varian Halcyon Cancer Treatment System

Image-guided system for intensity modulated radiotherapy used on 80-year-old male with head and neck cancer

UZ Leuven Treats First European Patient on Varian Halcyon Cancer Treatment System

October 25, 2017 — Varian recently announced an 80-year-old male with head and neck cancer became the first patient in Europe to be treated on the Halcyon system at University Hospitals Leuven (UZ Leuven) in Belgium. Halcyon is an advanced cancer treatment system that is more comfortable for the patient while delivering ease-of-use for healthcare providers, accelerated installation timeframes, expedited commissioning, simplified training and automated radiation therapy treatment.

Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), according to Varian, and is designed to expand the availability of high-quality cancer care globally. It is well-suited to handle the majority of cancer patients, offering advanced treatments for lung, esophagus, brain, head and neck, and many other forms of cancer.

"We selected the Halcyon system because of its potential to accelerate the treatment workflow and allow for a much closer connection between the patient and therapist," said Prof. Karin Haustermans, M.D., chair of the department, UZ Leuven. "Having now completed our first treatments I can say that Halcyon lived up to its promise of a more efficient workflow and better integration of imaging and treatment, which resulted in a much faster overall treatment time."

For more information: www.varian.com

Related Content

Accuray Incorporated announced the company has received CE Mark certification for its ClearRT helical fan-beam kVCT imaging capability.
News | Radiation Therapy | June 11, 2021
June 11, 2021 — Accuray Incorporated announced the company has received CE Mark certification for its...
Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

News | Radiation Oncology | June 02, 2021
June 2, 2021 — A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional rad
The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

News | Radiation Therapy | May 21, 2021
May 21, 2021 — An experimental drug that has shown promise in protecting healthy tissue from collateral damage caused
The drug, known as Avasopasem manganese, is made by Galera Therapeutics. It acts like a natural enzyme called superoxide dismutase and converts superoxide into hydrogen peroxide. Based on its ability to "mop up" damaging superoxide molecules, which are produced by radiation treatment, the drug is currently in clinical trials to test its ability to protect mucosal tissue from the side-effect of radiotherapy.

Getty Images

News | Radiation Therapy | May 19, 2021
May 19, 2021 — A small drug molecule that appears to protect normal tissue from the damaging effects of...